- Home
- RGNX
RGNX
REGENXBIO Inc.
as 10-31-2025 9:58am EST
Regenxbio Inc is a biotechnology company. Its main activity is the development and commercialization of recombinant adeno associated virus gene therapy to correct an underlying genetic defect. The diseases that the Regenxbio platform targets are metabolic (homozygous familial hypercholesterolemia), neurodegenerative conditions (mucopolysaccharidosis), and retinal diseases (wet age-related macular degeneration, X-linked retinitis pigmentosa). The company derives the majority of its revenue from the United States.
Upcoming Earnings Alert:
Get ready for potential market movements as REGENXBIO Inc. RGNX prepares to release earnings report on 06 Nov 2025.
| Founded: | 2008 | Country: | United States |
| Employees: | N/A | City: | ROCKVILLE |
| Market Cap: | 661.2M | IPO Year: | 2015 |
| Target Price: | $30.00 | AVG Volume (30 days): | 602.9K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 7 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -3.43 | EPS Growth: | N/A |
| 52 Week Low/High: | $5.04 - $13.93 | Next Earning Date: | 11-06-2025 |
| Revenue: | $155,782,000 | Revenue Growth: | 74.95% |
| Revenue Growth (this year): | 198.02% | Revenue Growth (next year): | 2.67% |
Stock Insider Trading Activity of REGENXBIO Inc. (RGNX)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Simpson Curran | RGNX | Chief Executive Officer | Sep 29 '25 | Sell | $10.03 | 7,624 | $76,468.72 | 236,973 |
Latest REGENXBIO Inc. News
RGNX Breaking Stock News: Dive into RGNX Ticker-Specific Updates for Smart Investing
PR Newswire
16 days ago
REGENXBIO to Participate in Upcoming Investor Conferences
PR Newswire
22 days ago
REGENXBIO Announces Presentation at the American Academy of Ophthalmology 2025 Annual Meeting
PR Newswire
25 days ago
REGENXBIO Announces Completion of Enrollment in Pivotal Trials of Subretinal Surabgene Lomparvovec for Wet AMD
Benzinga
2 months ago
Regenxbio Unveils 12-Month Data For Gene Therapy Soon After FDA Delays Review Date
MT Newswires
2 months ago
Sector Update: Health Care Stocks Mixed Pre-Bell Friday
MT Newswires
2 months ago
Regenxbio Says Longer-Term Trial Data Show RGX-121's Ability to Improve Outcomes for Hunter Syndrome Patients
PR Newswire
2 months ago
REGENXBIO Presents Positive Twelve-Month Pivotal Data from Phase I/II/III CAMPSIITE® Trial of RGX-121 for Treatment of MPS II
Barrons.com
4 months ago
Gene Therapy Was the Biggest Idea in Biotech. Now It Has Lost Support on Wall Street.
Compare RGNX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "RGNX REGENXBIO Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.